within Pharmacolibrary.Drugs.C_CardiovascularSystem.C03A_LowCeilingDiureticsThiazides.C03AB06_TrichlormethiazideAndPotassium;
model TrichlormethiazideAndPotassium 
   extends Pharmacolibrary.Drugs.ATC.C.C03AB06;

  annotation(Documentation(
    info ="<html><body><p>Trichlormethiazide is a thiazide diuretic used to treat hypertension and edema, frequently in combination with potassium chloride to prevent hypokalemia. This drug combination is used to maintain electrolyte balance while providing diuretic effects. Trichlormethiazide is approved for use in several countries but is less commonly used today compared to other thiazides.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults; no published human population PK models for trichlormethiazide and potassium combination were found.</p><h4>References</h4><ol><li><p>Nagashima, K, et al., &amp; Karasawa, A (1995). Protective effects of KW-3902, an adenosine A1-receptor antagonist, against cisplatin-induced acute renal failure in rats. <i>Japanese journal of pharmacology</i> 67(4) 349–357. DOI:<a href=&quot;https://doi.org/10.1254/jjp.67.349&quot;>10.1254/jjp.67.349</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7650867/&quot;>https://pubmed.ncbi.nlm.nih.gov/7650867</a></p></li><li><p>Takahashi, H, et al., &amp; Sugito, K (1985). Effects of magnesium oxide on trichlormethiazide bioavailability. <i>Journal of pharmaceutical sciences</i> 74(8) 862–865. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600740812&quot;>10.1002/jps.2600740812</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4032271/&quot;>https://pubmed.ncbi.nlm.nih.gov/4032271</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end TrichlormethiazideAndPotassium;
